Diabetes Type 1EPICAM-G6NCT07048795
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
An observational study of Diabetes Type 1, run by mylife Diabetes Care AG at 22 sites in France.
Trial summary
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France. The study is conducted among participants with type 1 diabetes (T1D) using the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the DEXCOM G6 Continuous… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Diabetes Type 1
- How many people
- 125 participants
- Where
- 22 sitesFrance
- Study dates
- 11 Dec 2025to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study population will be recruited from 22 French participating centers, which are defined as insulin pump initiation hospital centers according to the definition of the Francophone Diabetic Society.
Who may be able to join
- Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucose sensor (any model) for at least 14 days prior to the date of installation of the mylife YpsoPump, with at least 70% coverage, under the same sensor.
- Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FX hybrid closed loop.
- Patient who received the information sheets and gave their consent to participate in the study and to the processing of their personal data.
- Adult patient who signed an informed consent form to participate in the study or minor patient whose parents signed an informed consent form for their child's participation in the study.
- Adult patient, minor patient old enough to complete the questionnaires or parent of a minor patient able to read and understand French.
- Adult patient / minor patient capable to complete the questionnaires or parent of a minor patient who agrees to complete the online self-questionnaires.
Who cannot join
- Patient who used a hybrid closed-loop system, a fully closed-loop system, or a do-it-yourself loop system, regardless of the brand or model, within the past 6 months.
- Patients participating or having participated in a clinical trial in the previous month that prevents them from participating in other studies.
- Patient or parent unable to give consent.
- Protected Patient (subject to a legal protection measure: guardianship, curatorship or legal safeguard).
- Patient with a contraindication to the prescription of the mylife CamAPS FX hybrid closed-loop ( according to the Instructions For Use, IFU).
- Patient with an unresolved skin condition in the area of sensor placement and/or in the tubing placement area (e.g. psoriasis, dermatitis herpetiformis, rash, staphylococcal infection).
Show all 9Show fewer
- Patient with unstable diabetic retinopathy requiring laser treatment.
- Patient with a concomitant condition or treatment that alters glucose metabolism and that, in the investigator's judgment, is likely to have a significant impact on glycemic control;
- Patient whose follow-up cannot be carried out by the centre (relocation planned within 12 months of inclusion).
Trial locations and contacts
22 sites in 1 country. Contact the study team or a site near you to ask about taking part.
22 sites in 1 country
France22 sites, 22 recruiting
- Recruiting
CHU Amiens
Amiens, 80054
- Recruiting
Hôtel Dieu-Pédiatrie
Angers, 49933
- Recruiting
CH Victor Dupouy
Argenteuil, 95107
- Recruiting
Hôpital Bois Guillaume
Bois-Guillaume, 76230
- Recruiting
CHU de Bordeaux
Bordeaux, 33000
- Recruiting
CHU Brest - Hôpital La Cavale Blanche
Brest, 29609
- Recruiting
Hôpital Femme Mère Enfant Lyon
Bron, 69677
- Recruiting
CHU Grenoble Alpes
Grenoble, 38042
- Recruiting
Groupe Hospitalier de la Rochelle Ré Aunis
La Rochelle, 17019
- Recruiting
Hospices Civils de Lyon DIAB-Ecare
Lyon, 69008
- Recruiting
Hôpital Européen
Marseille, 13003
- Recruiting
Hôpital Europeen Georges Pompidou
Paris, 75015
- Recruiting
Hôpital Universitaire Necker Enfants Malades
Paris, 75015
- Recruiting
Groupe hospitalier Bichat Claude Bernard
Paris, 75018
- Recruiting
CH Périgueux
Périgueux, 24000
- Recruiting
CHU Poitiers
Poitiers, 86021
- Recruiting
Hôpital NOVO, Site Pontoise
Pontoise, 95300
- Recruiting
CHU Toulouse
Toulouse, 31059
- Recruiting
Clinique Pasteur
Toulouse, 31300
- Recruiting
CHRU Nancy-Hôpitaux de Brabois Adultes
Vandœuvre-lès-Nancy, 54511
- Recruiting
CH Bretagne Atlantique
Vannes, 56017
- Recruiting
Hôpital Robert Schuman-UNEOS
Vantoux, 57070
About this study
Official title: Impact de l'Utilisation du système Mylife CamAPS FX associé au Capteur DEXCOM G6 Sur le contrôle glycémique et la qualité de Vie de Patients DT1, en Vie réelle, en France
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France. The study is conducted among participants with type 1 diabetes (T1D) using the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the DEXCOM G6 Continuous Glucose Monitoring (CGM) sensor (the System).
The main objective of the study is to evaluate, under real-life conditions, the impact of the System on glycemic control in participants with T1D after one year of use.
Read more
Secondary objectives include assessing participant-reported outcomes, such as quality-of-life, treatment satisfaction, fear of hypoglycemia, and sleep quality, describing complications related to the system, the rate of hybrid closed-loop usage over one year, and analyzing system usage parameters.
The study will involve approximately 125 participants (including 100 adults and 25 minors) across 22 centers in France. Patients will be followed up for 12 months.
Read the detailed description
This study, called EPICAM-PMCF-G6, is part of a Post-Market Clinical Follow-up (PMCF) requested by the French Health Technology Assessment Committee (CNEDiMTS), following the listing of the System for reimbursement under the national healthcare system in France.
- Conditions
- Diabetes Type 1
- Being tested
- No Intervention: Observational Cohort
- Keywords
- Diabetes Mellitus, Type 1, Real-life use, mylife CamAPS FX, YpsoPump, Hybrid closed loop
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
No intervention
| Study group | Role | What they receive |
|---|---|---|
| Participants with type 1 diabetes initiating the hybrid closed-loop system | Participants (adults and minors) with type 1 diabetes (T1D) initiating the mylife CamAPS FX system combined with the Dexcom G6 sensor, under real-life management conditions Receives: Other: No Intervention: Observational Cohort |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Time in Range (TIR)
Change in Time in Range (TIR, 70-180 mg/dL; for pregnant women: TIR, 63-140 mg/dL) (%)
Measured: Baseline and 3 months
Secondary outcomes (17)
Change in Time in Range (TIR)
Change in Time in Range (TIR, 70-180 mg/dL; for pregnant women: TIR, 63-140 mg/dL) (%)
Measured: Baseline and 12 months
Change in Time In Tight Range (TITR)
Change in Time In Tight Range (TITR, 70 - 140 mg/dL) (%)
Measured: Baseline, 3 and 12 months
Change in Time Above Range (TAR)
Change in Time Above Range (TAR, > 250 mg/dL and > 180 mg/dL; for pregnant women: TAR, > 140 mg/dL) (%)
Measured: Baseline, 3 months, and 12 months
Change in Time Below Range (TBR)
Change in Time Below Range (TBR, < 70 mg/dL and < 54 mg/dL; for pregnant women: TBR, < 63 mg/dL and < 54 mg/dL) (%)
Measured: Baseline, 3 and 12 months
Change in average glucose levels from CGM sensor data
Change in average glucose levels from CGM sensor data (mg/dL)
Measured: Baseline, 3 months and 12 months
Change in Standard Deviation (SD) of glucose
Change in Standard Deviation (SD) of glucose
Measured: Baseline, 3 months and 12 months
Change in Coefficient of Variation (CV) of glucose
Change in Coefficient of Variation (CV) of glucose derived from CGM sensor data (%)
Measured: Baseline, 3 months and 12 months
Change in Glucose Management Indicator (GMI)
Change in Glucose Management Indicator (GMI) (%) derived from CGM sensor data
Measured: Baseline, 3 months and 12 months
Change in HbA1c
Change in HbA1c (%)
Measured: Baseline, 3 months and 12 months
Time in hybrid closed-loop
Time spent in hybrid closed-loop (%)
Measured: 3 months and 12 months
System usage modalities
Description of evolution rate of advanced features
Measured: 3 months and 12 months
Change in the PAID questionnaire score
Self-administered questionnaire: Problem Areas In Diabetes (PAID)
Following versions will be used: Adult version (18 and above), Teen version (PAID-T) in adolescents aged 12-18 years, and for their parents (P-PAID-T), Children version (PAID-C) in children aged 8-11 years and their parents (P-PAID-C). P-PAID-C will be also used in parents of children aged <8 years.
The Problem Areas in Diabetes (PAID) questionnaire assesses diabetes-related emotional distress across patients and caregivers using age- and role-specific versions. The PAID (adults), PAID-T (teens), and PAID-C (children) are self-reported, while P-PAID-T and P-PAID-C are completed by parents of teens and children, respectively. All versions use Likert scales and are typically transformed to a 0-100 score, with higher values indicating greater distress.
Measured: Baseline, 3 months and 12 months
Change in the DTSQ questionnaire score
Self-administered questionnaire: Diabetes Treatment Satisfaction Questionnaire (DTSQs)
Following versions will be used: Adult version (18 and above), Teen version (DTSQs-Teen) in adolescents aged 13-18 years. For their parents and parents of children aged <13 years, Parent version (DTSQs-Parent) will be used.
DTSQQs for adults contains 8 items, DTSQs-Teen has 12 items and DTSQs-Parent has 14 items. The total score of the DTSQs is calculated by summing six items (excluding perceived hypo/hyperglycaemia), each rated 0 to 6, resulting in a total score from 0 to 36, with higher scores indicating better treatment satisfaction.
Measured: Baseline, 3 months and 12 months
Change in the HFS-II questionnaire score
Self-administered questionnaire Hypoglycemia Fear Survey II (HFS-II).
The following versions will be used: Adult version, Children version (HFS-II children) for children aged 6 years and above, Parent version (HFS-II parent) for children aged 8 years and above, and Parent version for children aged <8 years (HFS-II parent of young children).
HFS-II consists of items ranging from 0 (never) to 4 (almost always) (9 items in the Adult version, 25 in the Teen version and 26 in the Parent versions). It is composed of two subscales: a Behavior score and a Worry score, with higher scores reflecting greater behavioral or emotional impact.
Measured: Baseline, 3 months and 12 months
Change in the PSQI questionnaire score
Self-administered questionnaire: Pittsburgh Sleep Quality Index (PSQI).
The questionnaire will be used in adults and parents. It contains 19 items which are grouped into 7 components that contribute to the overall score. Each component is scored from 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty. The 7 component scores are summed to produce a total score ranging from 0 to 21.
Measured: Baseline, 3 months and 12 months
Perceived changes in quality of life, treatment satisfaction, fear of hypoglycemia, and sleep quality
Participant reported perceived changes in quality of life, treatment satisfaction, fear of hypoglycemia and sleep quality measured with a question " Patient Global Impression of Change " (PGIC) (one for each dimension).
Each PGIC will be used in adults, parents and children aged 11 years and above and consisting of one question with 7 modalities from 'Much worse" to "Much better".
Measured: Baseline, at 3 months and 12 months
Safety / Adverse events related to the use of the System
Number of diabetic ketoacidosis events, severe hypoglycemia requiring assistance (medical and non-medical), unplanned hospitalizations related to diabetes and other complications related to the use of the system that meet the predefined acceptance criteria based on safety parameters for the target devices.
Measured: 3 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2025
- Study start11 Dec 2025
- Primary completionMar 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Type 1Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- mylife Diabetes Care AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Qualees SAS, CamDiab Ltd
- Responsible party
- Sponsor
- Investigators
- Ingo Braun, Study director, mylife Diabetes Care
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07048795
- Sponsor's protocol ID
- 2024-A00207-40
- Acronym
- EPICAM-G6
- Status last verified
- Jul 2026
- First submitted
- 24 Jun 2025
- Last updated
- 9 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: In accordance with the General Data Protection Regulation and French data protection laws the presentation of the results derived from data processing shall under no circumstances allow the direct or indirect identification of individuals participating in the study. In the event of publication of the study findings in a scientific journal, access to the data by an independent expert - including one appointed by a scientific publisher - shall only be granted through the interface provided or designated by the Data Controller, solely for the purpose of verifying or reproducing the analyses, and exclusively under the conditions defined for secure consultation and data handling. The study is a non-interventional trial.
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact de l'Utilisation du système Mylife CamAPS FX associé au Capteur DEXCOM G6 Sur le contrôle glycémique et la qualité de Vie de Patients DT1, en Vie réelle, en France
- ClinicalTrials.gov ID
- NCT07048795
- Acronym / sponsor ID
- EPICAM-G6 / 2024-A00207-40
- Conditions
- Diabetes Type 1
- Keywords
- Diabetes Mellitus, Type 1, Real-life use, mylife CamAPS FX, YpsoPump, Hybrid closed loop
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 125 participants (estimated)
- Lead sponsor
- mylife Diabetes Care AGIndustry (pharma, biotech, devices)
- Collaborators
- Qualees SAS, CamDiab Ltd
- Study start
- 11 Dec 2025 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 2 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France. The study is conducted among participants with type 1 diabetes (T1D) using the mylife CamAPS FX hybrid closed-loop insulin delivery system combined with the DEXCOM G6 Continuous Glucose Monitoring (CGM) sensor (the System).
The main objective of the study is to evaluate, under real-life conditions, the impact of the System on glycemic control in participants with T1D after one year of use.
Secondary objectives include assessing participant-reported outcomes, such as quality-of-life, treatment satisfaction, fear of hypoglycemia, and sleep quality, describing complications related to the system, the rate of hybrid closed-loop usage over one year, and analyzing system usage parameters.
The study will involve approximately 125 participants (including 100 adults and 25 minors) across 22 centers in France. Patients will be followed up for 12 months.
Detailed description
This study, called EPICAM-PMCF-G6, is part of a Post-Market Clinical Follow-up (PMCF) requested by the French Health Technology Assessment Committee (CNEDiMTS), following the listing of the System for reimbursement under the national healthcare system in France.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants with type 1 diabetes initiating the hybrid closed-loop system | – | Other: No Intervention: Observational CohortParticipants (adults and minors) with type 1 diabetes (T1D) initiating the mylife CamAPS FX system combined with the Dexcom G6 sensor, under real-life management conditions |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study population will be recruited from 22 French participating centers, which are defined as insulin pump initiation hospital centers according to the definition of the Francophone Diabetic Society.
Key inclusion criteria (6 listed)
- Patients with type 1 diabetes who have been using a Dexcom or Abbott Libre glucose sensor (any model) for at least 14 days prior to the date of installation of the mylife YpsoPump, with at least 70% coverage, under the same sensor.
- Patient for whom the diabetes specialist decides to initiate the mylife CamAPS FX hybrid closed loop.
- Patient who received the information sheets and gave their consent to participate in the study and to the processing of their personal data.
- Adult patient who signed an informed consent form to participate in the study or minor patient whose parents signed an informed consent form for their child's participation in the study.
- Adult patient, minor patient old enough to complete the questionnaires or parent of a minor patient able to read and understand French.
Key exclusion criteria (9 listed)
- Patient who used a hybrid closed-loop system, a fully closed-loop system, or a do-it-yourself loop system, regardless of the brand or model, within the past 6 months.
- Patients participating or having participated in a clinical trial in the previous month that prevents them from participating in other studies.
- Patient or parent unable to give consent.
- Protected Patient (subject to a legal protection measure: guardianship, curatorship or legal safeguard).
- Patient with a contraindication to the prescription of the mylife CamAPS FX hybrid closed-loop ( according to the Instructions For Use, IFU).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortNo intervention | Other | Participants with type 1 diabetes initiating the hybrid closed-loop system |
Primary outcome
Change in Time in Range (TIR)
Time frame: Baseline and 3 months
Change in Time in Range (TIR, 70-180 mg/dL; for pregnant women: TIR, 63-140 mg/dL) (%)
17 secondary outcomes
Change in Time in Range (TIR)
Time frame: Baseline and 12 months
Change in Time In Tight Range (TITR)
Time frame: Baseline, 3 and 12 months
Change in Time Above Range (TAR)
Time frame: Baseline, 3 months, and 12 months
Change in Time Below Range (TBR)
Time frame: Baseline, 3 and 12 months
Change in average glucose levels from CGM sensor data
Time frame: Baseline, 3 months and 12 months
Change in Standard Deviation (SD) of glucose
Time frame: Baseline, 3 months and 12 months
Change in Coefficient of Variation (CV) of glucose
Time frame: Baseline, 3 months and 12 months
Change in Glucose Management Indicator (GMI)
Time frame: Baseline, 3 months and 12 months
Change in HbA1c
Time frame: Baseline, 3 months and 12 months
Time in hybrid closed-loop
Time frame: 3 months and 12 months
System usage modalities
Time frame: 3 months and 12 months
Change in the PAID questionnaire score
Time frame: Baseline, 3 months and 12 months
Change in the DTSQ questionnaire score
Time frame: Baseline, 3 months and 12 months
Change in the HFS-II questionnaire score
Time frame: Baseline, 3 months and 12 months
Change in the PSQI questionnaire score
Time frame: Baseline, 3 months and 12 months
Perceived changes in quality of life, treatment satisfaction, fear of hypoglycemia, and sleep quality
Time frame: Baseline, at 3 months and 12 months
Safety / Adverse events related to the use of the System
Time frame: 3 months and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Individual participant dataSharing planned: No. In accordance with the General Data Protection Regulation and French data protection laws the presentation of the results derived from data processing shall under no circumstances allow the direct or indirect identification of individuals participating in the study. In the event of publication of the study findings in a scientific journal, access to the data by an independent expert - including one appointed by a scientific publisher - shall only be granted through the interface provided or designated by the Data Controller, solely for the purpose of verifying or reproducing the analyses, and exclusively under the conditions defined for secure consultation and data handling. The study is a non-interventional trial.
Related trials for Diabetes Type 1
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ingo Braun study director
mylife Diabetes Care
22 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Type 1, run by mylife Diabetes Care AG at 22 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 22 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ingo Braun, Dr. (+41582347132, clinical-studies@mylife-diabetescare.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Time in Range (TIR) (time frame: Baseline and 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.